Livzon Pharmaceutical Group ( (HK:1513) ) has shared an announcement.
Livzon Pharmaceutical Group Inc. has announced its annual general meeting for 2024, scheduled for May 29, 2025, in Zhuhai, China. The meeting will address several key resolutions, including the approval of the 2024 work reports, financial accounts, and annual report, as well as the re-appointment of Grant Thornton as the company’s auditor. Additionally, the meeting will consider the 2024 annual profit distribution plan, which proposes a cash dividend of RMB11.00 per 10 shares, and the renewal of the company’s A Shares Repurchase Scheme. These resolutions are significant for stakeholders as they outline the company’s financial strategy and governance for the upcoming year.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products and services, with a market focus on both domestic and international sectors.
YTD Price Performance: -0.29%
Technical Sentiment Signal: Buy
Current Market Cap: $3.93B
For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.